Alendronate prevents bone loss in Chinese women with osteoporosis
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要The objectives of the Hong Kong study are to investigate the efficacy of 10 mg alendronate in preventing bone loss at the hip and spine in osteoporotic Chinese women. One hundred osteoporotic Chinese women, aged 60-79 years, were randomized to receive 10 mg of alendronate or placebo, with 500 mg elemental calcium. Bone mineral density (BMD) at the spine and hip were measured at baseline, 6 months, and 12 months. Seventy-eight subjects completed the study. The alendronate-treated group gained more bone at both the spine (p < 0.01) and femoral neck (p < 0.001), with a mean difference (+/-SE) of 2.4% (+/-0.86%) at the spine and 3.98% (+/-0.95%) at the femoral neck. Of the 100 patients, 6 subjects in the alendronate group and 5 subjects in the placebo group had mild gastrointestinal symptoms. We conclude that alendronate (10 mg) was effective in preventing bone loss in postmenopausal osteoporotic Chinese women. (C) 2000 by Elsevier Science Inc. All rights reserved.
著者Lau EMC, Woo J, Chan YH, Griffith J
期刊名稱BONE
出版年份2000
月份11
日期1
卷號27
期次5
出版社ELSEVIER SCIENCE INC
頁次677 - 680
國際標準期刊號8756-3282
電子國際標準期刊號1873-2763
語言英式英語
關鍵詞alendronate; bone mass; Chinese; osteoporosis; postmenopausal women
Web of Science 學科類別Endocrinology & Metabolism; ENDOCRINOLOGY & METABOLISM

上次更新時間 2020-14-09 於 03:34